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Abstract: Osteoarthritis (OA) is a degenerative joint disease accompanied by pain and loss of
function. Adipose tissue harbors mesenchymal stem/stromal cells (MSC), or medicinal signaling
cells as suggested by Caplan (Caplan, 2017), used in autologous transplantation in many clinical
settings. The aim of the study was to characterize a stromal vascular fraction from microfragmented
lipoaspirate (SVF-MLA) applied for cartilage treatment in OA and compare it to that of autologous
lipoaspirate (SVF-LA). Samples were first stained using a DuraClone SC prototype tube for
the surface detection of CD31, CD34, CD45, CD73, CD90, CD105, CD146 and LIVE/DEAD
Yellow Fixable Stain for dead cell detection, followed by DRAQ7 cell nuclear dye staining,
and analyzed by flow cytometry. In SVF-LA and SVF-MLA samples, the following population
phenotypes were identified within the CD45– fraction: CD31+CD34+CD73±CD90±CD105±CD146±
endothelial progenitors (EP), CD31+CD34–CD73±CD90±CD105–CD146± mature endothelial cells,
CD31–CD34–CD73±CD90+CD105–CD146+ pericytes, CD31–CD34+CD73±CD90+CD105–CD146+
transitional pericytes, and CD31–CD34+CD73highCD90+CD105–CD146– supra-adventitial-adipose
stromal cells (SA-ASC). The immunophenotyping profile of SVF-MLA was dominated by a reduction
of leukocytes and SA-ASC, and an increase in EP, evidencing a marked enrichment of this cell
population in the course of adipose tissue microfragmentation. The role of EP in pericyte-primed
MSC-mediated tissue healing, as well as the observed hormonal implication, is yet to be investigated.
Keywords: lipoaspirate; microfragmented lipoaspirate; immunophenotyping; endothelial progenitors;
pericytes; supra-adventitial adipose stromal cells
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1. Introduction
Ever since the discovery that human adipose tissue is a rich source of mesenchymal stem/stromal
cells (MSC) and is bestowed with therapeutic potential after culture expansion and differentiation [1–3],
autologous adipose tissue has been explored for its regenerative properties in many clinical settings.
MSC are contained within the stromal vascular fraction (SVF)—the aqueous portion obtained after
enzymatic digestion of lipoaspirate (LA)—together with other cells of the differentiated or multipotent
features. The success of tissue regeneration has been attributed to the activated MSC excreting
bioactive molecules that inhibit scar formation and stimulate angiogenesis. The immunomodulatory
and regenerative properties of MSC acting in a paracrine manner provoked the re-naming of these
cells as medicinal signaling cells (MSC) [4,5].
Lipogems® technology has emerged as a platform that yields an intact SVF and MSC of a high
therapeutic potential (reviewed in [6]), obtained by the microfragmentation of autologous fat tissue [7].
The use of such microfragmented lipoaspirate (MLA) has reached a fruitful application in osteoarthritis
(OA), one of the leading musculoskeletal disorders in the adult population worldwide [8]. A prospective
non-randomized interventional study using a single intra-articular injection of autologous MLA resulted
in a successful osteoarthritic cartilage treatment, as evidenced by an increased glycosaminoglycan
content and an improved mechanical axis of the patient lower extremities [9]. The microfragmentation
of adipose tissue is considered to empower tissue regeneration by boosting the secretory ability of MSC.
As shown recently, the secretome of microfragmented adipose tissue is abundantly rich in cytokines
and angiogenic factors [10]. Although clinical implementation of MLA has expanded and yielded
impressive results in tissue healing (especially in orthopedia and reconstitutive surgery), a more precise
cellular characterization to correlate explanatory aspects is still called for. As demonstrated previously
by flow cytometry analysis of human lipoaspirate, the SVF is comprised of endothelial progenitor
(EP) cells (CD31+CD34+CD146+), endothelial mature (EM) cells (CD31+CD34–CD146±), pericytes
(CD31–CD34–CD146+), supra-adventitial-adipose stromal cells (SA-ASC) (CD31–CD34+CD146–) and
the transitional pericytes (TP) (CD31–CD34+CD146+), exhibiting various expressions of the CD73, CD90
and CD105 mesenchymal markers [11]. A recent paper by Vezzani et al. analyzed adipose-derived
perivascular MSC obtained by microfragmentation, and documented a marked domination of pericytes
over the SA-ASC, as compared to autologous lipoaspirate-derived SVF [10]. In this study, we applied a
more comprehensive approach by polychromatic flow cytometry in order to unambiguously define
the multipotent cellular composition and ratios in the SVF from LA or MLA, based on the previous
papers [10–12].
2. Materials and Methods
2.1. Patients
The study involved twelve patients with OA (six males and six females, aged 30–81) receiving
intra-articular knee injection of autologous MLA in the Specialty Hospital St. Catherine (Zabok, Croatia),
as described in Hudetz et al. [8]. The LA and MLA patient samples were delivered to the Srebrnjak
Children’s Hospital (Zagreb, Croatia) and stored overnight at room temperature (RT) protected from
light before further processing [13,14]. The study was approved by the local Institutional Review Board
(No. EP 001/2016) and the hospital Research Ethics Committee (No. 11/2017).
2.2. Stromal Vascular Fraction Isolation
To maximize the SVF yield from both sample sources and properly prepare cells for flow cytometry,
we equally treated LA and MLA samples with 1% collagenase type I in Dulbecco’s Modified Eagle
Medium (D-MEM) (both from Sigma-Aldrich, Saint Louis, MO, USA) in a shaking bath at 37 ◦C
for 45 min. After 1:2 dilution with 2% fetal bovine serum (Biosera, Nuaille, France) in D-MEM
(Sigma-Aldrich), samples were filtrated through a 100 µm-cell strainer (BD Falcon, Corning, NY, USA)
and centrifuged at 300 g for 10 min at RT. Supernatants were discarded and cell pellet resuspended
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in 1 mL of the VersaLyse solution (Beckman Coulter, Miami, FL, USA). After 10 min, samples were
filtered through a 40 µm-cell strainer (BD Falcon, Corning, NY, USA), centrifuged at 300 g for 10 min at
RT and the cell pellet resuspended in D-MEM (Sigma-Aldrich). The cells were counted on the Sysmex
XT1800 counter (Sysmex, Kobe, Japan).
2.3. Flow Cytometry
SVF cells isolated from LA (SVF-LA) or MLA (SVF-MLA) were stained using a Duraclone SC
dry reagent prototype tube (kindly provided by Beckman Coulter, Miami, FL, USA). The Duraclone
SC tube is a polychromatic reagent that allows the identification of MSC subpopulations based on
the use of antibodies specific for the cell surface markers: CD31, CD34, CD45, CD73, CD90, CD105,
and CD146, labeled with PB, ECD, APC-AF750, PE, FITC, CD45-PC7, and PC5.5 fluorochromes,
respectively, and Live/Dead Yellow Fixable Stain (ThermoFisher, Waltham, MA, USA) for 20 min at
RT protected from light, fixed with 2% paraformaldehyde (Electron Microscopy Sciences, Hatfield,
PA, USA) in phosphate-buffered saline (PBS; Sigma-Aldrich), washed, permeabilized with PermWash
(BD Biosciences, San Jose, CA, USA) and the cell nuclei stained with the DRAQ7 dye (BioStatus,
Shepshed, UK). Forward scatter (FCS) data files were analyzed using the FlowLogic software (Inivai
Technologies, Mentone, Australia). The data about reproducibility of staining with Duraclone SC tube
can be found in Table S1. More details about the instrument configuration, daily quality control, reagents
used and data analysis can be found in Table S2.
2.4. Statistical Analysis
For data that passed the normality test, a parametric paired t-test, unpaired t-test, or one-way
analysis of variance (ANOVA) with Sidak’s multiple comparison test was used. For data that failed
the normality test, a nonparametric Wilcoxon test was applied to calculate the statistics (GraphPad
Prism 6 for Windows; GraphPad Software, Inc., San Diego, CA, USA). A p-value < 0.05 was considered
statistically significant.
3. Results
3.1. Immunophenotyping Analysis of Stromal Vascular Fraction from Lipoasirate and Microfragmented
Lipoasirate Samples by Polychromatic Flow Cytometry
The gating strategy and subpopulation determination are shown in Figure 1A–D, Figure 2A–D,
Figure 3A–D and Figure S1. The inclusion of a DNA dye was crucial to identify and select nucleated
cells from the mixture of the remaining cell debris, red blood cells and oil residues. CD45– and
CD45+ SVF cells were determined in both lipoaspirate (SVF-LA) and its microfragmented lipoaspirate
counterpart (SVF-MLA), and viability determined. The viability of nucleated CD45– was 94% ± 1.54%
for LA and 94.8% ± 1.2% for MLA, and the viability of nucleated CD45+ cells was 93.7% ± 1.2% for LA
and 94.4% ± 1.6% for MLA (Figure 4A,B). Only live cells were selected for further analysis (Figure 1D).
We identified the five CD45– subpopulations of SVF-LA and SVF-MLA as being:
CD31+CD34+CD73±CD90±CD105±CD146± EP, CD31+CD34–CD73±CD90±CD105–CD146± EM,
CD31–CD34–CD73±CD90+CD105–CD146+ pericytes, CD31–CD34+CD73±CD90+CD105–CD146+TP,
and CD31–CD34+CD73highCD90+CD105–CD146– supra-adventitial adipose stromal cells (Figure 2A–D
and Figure 3A–D). In all the samples, the average percentage of EM and TP was always below 2% of
the total nucleated cells, and therefore the data from these populations were not included in further
analysis. The four major determined phenotypes are summarized in Table 1.
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Figure 1. Gating strategy, expression of the CD45 cell surface marker and cell viability in stromal vascular 
fraction (SVF) cells obtained from lipoaspirate (SVF-LA) or its microfragmented lipoaspirate (SVF-MLA) 
counterpart. Singlet cell selection was performed on forward scatter (FCS) time of flight (TOF) and FSC area 
signals density plot (A). Only events from nucleated cells were analyzed further, based on the DNA-binding 
DRAQ7 dye-positivity and side scatter (SSC) (B). Nucleated CD45+ and CD45- cells were discerned (C), and live 
CD45- cells (D) and CD45+ cells determined. 
 
Figure 2. Nucleated CD45- live cells were analyzed for the presence of the CD31 and CD34 lineage specific 
surface markers. Endothelial mature (EM), endothelial progenitor (EP) and non-endothelial cells were identified 
as CD31+CD34-, CD31+CD34+ and CD31-CD34- cells, respectively (A,B). Non-endothelial cells were analyzed 
further for CD146 expression in combination with CD34 to discern pericytes, transitional pericytes (TP) and 
supra-adventitial-adipose stromal cells (SA-ASC) in SVF-LA and SVF-MLA samples (C,D).  
Figure 1. Gating strategy, expression of the CD45 cell surface marker and cell viability in stromal
vascular fraction (SVF) cells obtained from lipoaspirate (SVF-LA) or its microfragmented lipoaspirate
(SVF-MLA) counterpart. Singlet cell selection was performed on forward scatter (FCS) time of flight
(TOF) and FSC area signals density plot (A). Only events from nucleated cells were analyzed further,
based on the DNA-binding DRAQ7 dye-positivity and side scatter (SSC) (B). Nucleated CD45+ and
CD45– cells were discerned (C), and live CD45– cells (D) and CD45+ cells determined.
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Figure 2. Nucl ated CD45– live cells were analyzed for the presence of the CD31 and CD34 lineage
specific surface markers. Endothelial mature (EM), endothelial progenitor (EP) and non-endothelial
cells were identified as CD31+CD34–, CD31+CD34+ and CD31–CD34– cells, respectively (A,B).
Non-endothelial cells were analyzed further for CD146 expression in combination with CD34 to
discern pericytes, transiti nal p ricytes (TP) a d supra- dventitial-adipose stromal cells (SA-ASC) in
SVF-LA and SVF-MLA samples (C,D).
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Figure 3. Expression of mesenchymal stem cell markers in SVF cells obtained from SVF-LA or its SVF-MLA 
counterpart. The co-expression of the mesenchymal-associated markers CD90 vs CD73 (A) and CD90 vs CD105 
(B) are shown for the three progenitor populations: endothelial progenitors, pericytes and SA-ASC. One 
representative experiment is shown. Summarized results of the determined immunophenotypes for the three 
progenitor populations and leukocytes are shown in Table 1, n = 12.  
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Figure 3. Expression of mesenchymal stem cell markers in SVF cells obtained from SVF-LA or its
SVF-MLA counterpart. The co-expression of the mesenchymal-associated markers CD90 vs CD73
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Figure 4. Cell viability in CD45– and CD45+ SVF cells obtained from SVF-LA or its SVF-MLA counterpart.
Table 1. Summarized results of the determined immunophenotypes and their frequency within
nucleated SVF cells for the thr e progenitor populations and leukocytes.
Immunophenotype Lineage Markers Mesenchymal Stem/Stromal
Cell (MSC) Mark r
Frequency within Nucleated SVF Cells
LA MLA
Endothelial progenitors CD45–CD31+CD34+CD146± CD73±CD90±CD105± 13–51% 45–89%
P ricytes CD45–CD31–CD34–CD146+ CD73±CD90+CD105– 10–21% 7–21%
SA-ASC CD45–CD31–CD34+CD146– CD73highCD90±CD105– 5–27% 1–9%
Leukocytes CD45+CD31–CD34-CD146– CD73–CD90–CD105– 11–58% 3–25%
± stands for a variable expression (negative and positive cells overlap).
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3.2. Stromal Vascular Fraction from Microfragmented Lipoasirate Significantly Differs in Cell Content from
Stromal Vascular Fraction from Lipoasirate
The relative amounts of the four subpopulations were expressed as a percentage of total nucleated
cells. The percentage of EP was significantly higher (Figure 5A) while the percentage of SA-ASC and
leukocytes was significantly lower in SVF-MLA compared to SVF-LA (Figure 5B,D). The percentage of
pericytes showed a donor-dependent variation and did not result in a significant difference between
SVF-LA and SVF-MLA (Figure 5C).
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Figure 5. Comparative analysis of four cell subpopulations in SVF obtained from SVF-LA or its
SVF-MLA counterpart. The quantitative data of the polychromatic flow cytometry analysis show the
difference in the percentage of the three progenitor cell types (A–C) and leukocytes (D) between the
SVF-LA and SVF-MLA of each donor. p-values from p < 0.01; (***) p < 0.001; (****) p < 0.0001; n = 12.
Given the literature data on pericyte-mediated tissue regeneration via activated MSC [6,10], we
were particularly interested in the ratio between pericytes and SA-ASC. As shown in Figure 6A, the
pericytes/SA-ASC ratio was significantly higher in SVF-MLA versus SVF-LA samples. Interestingly,
samples with the highest pericytes/SA-ASC ratio originated from male patients, and this was significantly
higher compared to female patients (Figure 6D). The EP/pericytes and EP/SA-ASC ratios were also
significantly higher in SVF-MLA compared to SVF-LA (Figure 6B,C), however, it did not show sex-related
difference in the former (Figure 6E,F).
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Figure 6. Comparative analysis of four cell subpopulations in SVF cells obtained from (SVF-LA
or its SVF-MLA counterpart. Graphs A–C show a difference in the ratios of the three progenitor
subpopulations between SVF-LA and SVF-MLA. Differences in the ratios of the three progenitor
subpopulations in the SVF-MLA samples between female and male patients are shown in graphs D–F.
p-values: (**) p < 0.01; (***) p < 0.001; n = 12.
4. Discussion
In an attempt to contribute to the growing need to understand the adipose tissue MSC used in
therapeutic intervention, we investigated the cell content of the MLA product applied for the treatment
of OA patients and its lipoaspirate counterpart [9,15]. We described five CD45– subpopulations of
SVF-LA and SVF-MLA, here described as being: CD31+CD34+CD73±CD90±CD105±CD146±EP cells,
CD31+CD34–CD73±CD90±CD105–CD146± EM cells, CD31–CD34–CD73±CD90+CD105–CD146+ pericytes,
CD31–CD34+CD73±CD90+CD105–CD146+ TP and CD31–CD34+CD73highCD90+CD105–CD146–SA-ASC.
The relative proportions of the determined nucleated populations, with the EP percentage prevailing over
SA-ASC and pericytes, as well as the expressions of the CD73 and CD105 mesenchymal markers differ
from what has been reported previously for non-microfragmented adipose tissue [11,12,16]. Although
some previous papers reported CD105 positivity on freshly isolated SVF-LA cells [16,17], we found
only a weak CD105 expression on pericytes and SA-ASC of either SVF-LA or SVF-MLA samples. The
observed differences could be ascribed to different adipose tissue extraction methods (abdominoplasty
versus lipoaspiration) and also the analysis approach, which in our case involves the calculation of the
subpopulation frequency of all nucleated events and not only of the non-leukocyte fraction.
With respect to microfragmented adipose tissue, we observed even more pronounced differences
in the proportions of the determined populations than seen in the lipoaspirate counterparts. To our
knowledge, this is the first comprehensive immunophenotyping of the SVF populations from MLA used
for therapeutic intervention. The analysis of SVF cell composition performed so far by flow cytometry
has been carried out by means of expressing a single marker-positivity, e.g., as CD34+ or CD146+
populations within nucleated CD45– cells in MLA [7]. Given that these are not population-specific
phenotypes, and that different subpopulations share certain markers, this approach does not provide a
precise content of the SVF subpopulations and their ratios. In a recent paper, Vezzani et al. applied a
similar approach to ours and reported a substantial pericyte increase after microfragmentation with
respect to the SA-ASC share [10]. We also found a marked domination of pericytes over SA-ASC, yet,
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our pericyte/SA-ASC ratio was even more pronounced (five times higher median value). Of note, the
authors did not specify the use of the DNA stain to exclude non-nucleated events from the analysis,
which might have caused a higher background and could have contributed to double negative events
influencing the observed proportions. Moreover, the authors focused only on pericytes and SA-ASC
while leaving out the other cell populations from the analysis.
Pericytes and SA-ASC, the presumed in vivo progenitors of MSC [18,19], have gained the
most attention in interpreting the medicinal effects of MSC used in clinical applications. However,
after microfragmentation, we surprisingly found the most prominent enrichment of EP cells, which
outnumbered both pericytes and SA-ASC. When MLA was applied as an autologous intra-articular
treatment in patients with late-stage knee OA, it improved clinical and functional outcomes in 85% of
the patients, who had before the study been candidates for a total knee replacement surgery [15]. The
fact that the applied MLA EP outnumbered the other SVF cells imposes their inevitable involvement in
the observed effects of MLA-mediated cartilage treatment. EP represent important players implicated in
vascularization as a prerequisite for wound repair and tissue regeneration [20,21]. Several in vitro and
in vivo studies have demonstrated proliferative, proangiogenic and vasculogenic effects of MSC–EP
interactions [22–25], as well as differentiation commitment [26,27]. A crosstalk between MSC–EP,
which can involve both paracrine mechanism and/or cell–cell contact (via platelet-derived growth
factor and its receptor (PDGF–PDGFR), and Notch-signaling) [23,28], seems to occur in different
conditions of tissue inflammation [29], suggesting that their interplay and beneficial effects might
also be accomplished in cartilage tissue repair and regeneration. We, therefore, hypothesized that a
plethora of cytokines, chemokines and growth factors, i.e., bioactive molecules hitherto ascribed to the
activated MSC, acting as medicinal signaling cells [5], perhaps stem from a synergistic effect of the
pericyte–MSC–EP interactions [15].
We furthermore found a marked decrease of the CD45+ leukocyte fraction in MLA, confirming the
previous reports on the reduction of proinflammatory elements by microfragmentation technology [7].
A lower inflammatory cytokine source presumably contributes to the repair process at the site of tissue
injury. However, the reduction of the CD45- population per se is not enough for the observed repair
effects which have been evidently ascribed to the MSC-induced vasculogenic and other factors [7].
The notion that in our hands the EP-pericyte ratio, as well as the pericyte-SA-ASC ratio, differed
between men and women implies that the presumed in vivo precursors of the MSC, as well as EP,
might be under the influence of sex hormone(s). In line with this, we noticed that in the paper
by Vezzani et al. [10], the sample source originated exclusively from female subjects and resembles
our female data, which besides technical and analytical disparities might partially explain the
above-mentioned lower pericyte/SA-ASC ratio in the cited paper. Interestingly, we did not observe
sex-related difference between EP and pericytes, the two most prevalent populations in microfragmented
products. The hormonal regulation of hematopoietic stem cells has already been evidenced [30],
and further attempts should be focused on the hormone-specific pathways of their adipose MSC
counterparts. It has been reported that estrogens may act upon the production of cytokines and growth
factors in human MSC as well as the level of circulating EP (reviewed in [31]). The results of the in vivo
studies are yet to explore the influence of autocrine estrogen production by MSC on their therapeutic
applications [32].
5. Conclusions
Taking into account our results, we have continued our clinical study enrolling a higher number
of participants, which will elucidate the observed sex disparity phenomenon. Ultimately, our goal
is to associate this clinical aspect with the secretome of the applied MLA product and the success of
the treatment outcome. Our results offer scientific support necessary to corroborate promising results
of clinical applications of the microfragmented product by elucidating structural niches that hold
functional impact. The pericyte–EP crosstalk has been documented intensely [33,34], and we believe
that the role of this axis in tissue regeneration cannot be neglected [35]. Given the intriguing result we
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found, we emphasize the importance of further investigation of these interactions in pericyte-mediated
MSC activation and, furthermore, in provoking angiogenic and anti-inflammatory features of MSC in
cartilage repair [36,37]. We also found a marked decrease in the CD45– leukocyte fraction, confirming the
previous reports on the reduction of proinflammatory elements by microfragmentation technology [7].
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